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and 9%, respectively. Compared with placebo, more patients achieved HbA1c
7% (39.4% vs 24.4%) and 8% (79.5% vs 60.6%) and fewer patients remained at or
worsened to HbA1c 9% (4.2% vs 13.9%) with dapagliflozin. CONCLUSIONS: Dapa-
gliflozin 10 mg/day reduced HbA1c across all baseline HbA1c categories; greater
reductions were seen in patients with higher baseline HbA1c. Substantially more
patients attained HEDIS HbA1c categories of7% and8% and substantially fewer
patients remained at orworsened toHbA1c9%with dapagliflozin, comparedwith
placebo. Collectively, dapagliflozin provided better glycemic control than placebo
over a range of HbA1c levels.
PDB9
COST-EFFECTIVENESS ANALYSIS OF SAXAGLIPTIN IN THE TREATMENT OF
TYPE 2 DIABETES MELLITUS IN RUSSIA
Arinina EE1, Rashyd M2
1Moscow Medical Academy, Moscow, Russia, 2City clinical hospital # 55 Department of
healthcare, Moscow, Russian Federation, Moscow, Russia
OBJECTIVES: To evaluate the long-term clinical and economic consequences of
saxagliptin in comparison with sulphonylurea available in the Russian market.
METHODS: The analysis is based on the Cardiff Long Term Model (Clarke et al.
2004). Three scenarios were developed and tested. Scenario 1 “trial based scenario”
(S1) the active treatment is saxagliptin (Onglyza®) added to metformin (MET),
which is compared to MET plus sulphonylurea (SU); input data are derived from
study D1680C00001 (Goke et al. 2010). Scenario 2 “real world scenario” (S2). Efficacy
and safety data taken from study D1680C00001, the cohort was taken from the
Russian Federal Diabetes Patient Register, time horizon was set to 40 years, HbA1c
threshold of 9.0% was assumed. Scenario 3 “MET monotherapy scenario” (S3). Ef-
ficacy and safety data taken from a study of DeFronzo et al. 2009. Patient demo-
graphic characteristics were the same as in Scenario 2; time horizon - nine years as
in the base case scenario 1. The cost-effectiveness analysis was performed from
the government health care system’s perspective. The costs applied were based on
prices listed in the essential drug list (MoH 2010) and official standards of treatment
developed by expert groups at the Ministry of Health level (Russian Federation).
RESULTS: In S1 - MET plus saxagliptin was associated with an incremental cost-
effectiveness ratio (ICER) of Russian Roubles (RUB) 38,840 per QALY gained, and
RUB 7,142,690 per life year gained (LYG) versus SU. In S2 - ICER of RUB 104,153 per
QALY gained and RUB 9,884,121 per life year. In S3 - ICER resulted in RUB 20,353,081
perQALYandRUB 29,044,346 per life year gained.CONCLUSIONS: In both scenarios
(1 and 2), assuming a willingness to pay threshold of RUB 800’000, saxagliptin
would be considered cost-effective in the Russian setting.
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OBJECTIVES: To assess the efficacy and safety of DPP-4 inhibitors, including sita-
gliptin, saxagliptin, vildagliptin and linagliptin, in type 2 diabetic patients.
METHODS: Both published and unpublished randomized controlled trials (RCTs)
for type 2 diabetic patients were selected if they: 1) compared DPP-4 inhibitors with
either placebo or another hypoglycemic; 2) had study duration of  12 weeks; and
3) had at least one baseline and post-treatment efficacy and/or safety outcome.
RESULTS: A total of 62 articles met the inclusion criteria. Seven of these trials
involved Japanese patients, but inclusion resulted in significant heterogeneity (I2
82%). Exclusion of these 7 trials resulted in a reduction of heterogeneity (I259%)
with a more stable pooled effect size. Analyses of the non-Japanese studeis (n55
RCTs) indicated that, compared to placebo, DPP-4 inhibitors were associatedwith a
reduction in hemoglobin (Hb) A1c (weightedmean difference (WMD) -0.65%; 95%
CI, -0.71 to -0.60) but a higher risk of hypoglycemia (Odds ratio (OR)  1.30; 95% CI,
1.01 to 1.68). A separate analysis of the 7 Japanese studies showed that, compared
to placebo, DPP-4 inhibitorswere associatedwith a greater reduction inHbA1c than
non-Japanese patients (WMD -1.67%; 95% CI, -1.89 to -1.44; P 0.05) and a non-
significant increase in risk of hypoglycemia (OR, 1.41; 95% CI, 0.51 to 3.88). When
comparing DPP-4 inhibitors to active comparators, the I2 was still high after sepa-
rating out Japanese studies. In the 17 active comparator trials, there was no signif-
icant difference in HbA1c reduction (WMD 0.04%; 95% CI, -0.09 to 0.16) or risk of
hypoglycemia (OR 0.60; 95% CI, 0.22 to 1.61) for DPP-4 inhibitors compared to
other anti-diabetic medications. CONCLUSIONS: Differences in efficacy and safety
were observed between Japanese and non-Japanese patients. The extent of HbA1c
reduction was more than doubled in trials including Japanese populations com-
pared to non-Japanese populations.
PDB11
HEALTH OUTCOMES OF INITIATING BASAL ANALOG INSULIN VIA DISPOSABLE
PENS AMONG PATIENTS WITH TYPE-2 DIABETES IN A NATIONAL MANAGED
CARE PLAN IN THE UNITED STATES
Pan C1, Tangirala M2, Wei W2, Lin J3
1Pro Unlimited, Boca Raton, FL, USA, 2Sanofi-Aventis, Bridgewater, NJ, USA, 3Novosys Health,
Flemington, NJ, USA
OBJECTIVES: To evaluate, in a US managed care setting, health outcomes among
patients with type 2 diabetes mellitus (T2DM) initiating basal insulin therapy via
disposable penwith insulin glargine (GLA-P) or insulin detemir (DET-P).METHODS:
Using the claim database from a US health plan (InVision™), T2DM patients initi-
ating GLA-P or DET-P were included if they were18 years, had continuous health
plan coverage for 6months before (baseline) and 1-year after initiation (follow-up),
with 1 prescription for oral antidiabetic drugs (OADs) and/or exenatide, but no
insulin use, during baseline. To minimize selection bias, stringent 1:1 propensity
score matching was used to balance baseline characteristics of the two cohorts.
Outcomesmeasures included 1-year treatment persistence and adherence, hemo-
globin A1c (A1C), hypoglycemia-related events, healthcare utilization and costs.
RESULTS: A totla of 5828 matched patients were included (n2914 in each cohort;
female 44.4%, baselinemean age 54.4 years; Charlson comorbidity index 0.55; num-
ber of OADs 2.60). During 1-year follow-up, patients initiating GLA-P, compared
with DET-P, were more persistent (58.8 vs. 44.1%, P0.001) and adherent (adjusted
medication possession ratio 0.68 vs. 0.66, P0.002) with treatment, had lower daily
insulin doses (DACON) (29.2 vs. 32.5 units/day, P0.012), similar rates of hypogly-
cemia-related events (5.9 vs. 6.6%, P0.281), lower diabetes prescription costs
(mean $3,142 vs. $3,372, P0.043) and marginally lower total health care costs
(mean $30,364 vs. $33,109, P0.086). Among patients with A1C data available
(GLA-P n356, DET-P n332), A1C at 1-year follow-up was 8.14% in GLA-P vs. 8.50%
in DET-P (P0.007), reflecting A1C reduction from baseline of 1.03 vs.0.86%
(P0.260). CONCLUSIONS: This real-world comparative study suggested that
among T2DM patients initiating basal analog insulins using disposable pen, com-
paredwithDET-P, GLA-Pmight be associatedwith increased treatment persistence
and adherence, similar rates of hypoglycemia, lower DACON and healthcare costs
during 1-year follow-up. This, however, should be confirmed in future pragmatic
randomized clinical trials.
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OBJECTIVES: Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin re-
ceptor blockers (ARBs) are recommended to reduce albuminuria, a risk factor for
nephropathy and all-cause mortality. The objective of the study was to compare
ACEIs and ARBs for development of end-stage renal disease (ESRD) development
and all-cause mortality in veteran patients with type 2 diabetes. METHODS: This
was a retrospective cohort study utilizing data in years 2002-2007 from the national
Department of Veterans Affairs (VA) databases. To be included in the sample pa-
tients had to be newly-diagnosed, new users of ACEIs or ARBs, and have a baseline
measure of albuminuria. Multivariate logistic regression models that assessed ef-
fect of ACEIs and ARBs on ESRD and all-cause mortality were estimated with con-
trols for risk factors of ESRD and all-causemortality, Elixhauser comorbidities, and
location of care. Propensity scores were used to adjust for differences in baseline
characteristics between ACEI and ARB patients. RESULTS:A total of 20,876 patients
using ACEIs (n18,947) or ARBs (n1929) met inclusion criteria. Mean follow-up
was two years. No significant differences were found between ACEIs and ARBs for
ESRD (1.12 [95% CI0.19-6.72]) and all-cause mortality (0.86 [95% CI0.24-3.07]).
Some comorbidities, however, had higher adjusted odds for ESRD (liver disease
odds ratio 7.40 [95% CI2.91-18.87]; fluid and electrolyte disorders odds ratio 7.71
[95% CI3.46-17.17]; deficiency anemias odds ratio 5.81 [95% CI2.40-14.09]) or
all-cause mortality (history of myocardial infarction odds ratio 2.85 [95% CI1.26-
6.46]), underlining the importance of prevention of these conditions.
CONCLUSIONS: There were no significant differences in ESRD and all-cause mor-
tality betweenACEIs and ARBs in this study that included patients from every state
in the United States, the District of Columbia, and Puerto Rico. Additionally, this
study shows that clinicians should focus educational efforts on disease prevention
due to downstream effects of certain conditions in patients with type 2 diabetes.
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OBJECTIVES: Turner syndrome (TS) is a chromosomal disorder that has total or
partial absence of chromosome X and haploinsufficiency of the SHOX gene. Fur-
thermore, it is associated with short stature with particular phenotype and hypo-
gonadism. Several studies have shown that the use of recombinant human growth
hormone (GH) in girls with TS raises final height. The aim of this study was to
describe the characteristics of a cohort of girls with TS diagnosed and treated with
GH in Colombia.METHODS: A cohort of 22 girls with TS, who entered to the drug-
international epidemiological record (KIGS) between 2004 and 2010were tracked in
Colombia. Girlswere diagnosedwith short stature and treatedwithGH therapy and
followed-up for 2 years. Tracking measures were: the time of starting therapy,
treatment regimens and clinical outcomes were estimated in terms of height mea-
sured by standard deviation units (SDS) and velocity growth in cm per year. Cohort
data was compared against literature findings published for girls treated on GH
with TS (Ranke MB et al 1988) and girls without GH treatment and TS (Tanner JM et
al 1976). RESULTS: Girls started GH therapy at a mean age of 7.03 years with a dose
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